NeoPhore Raises Additional £9.6M in Series B  Extension Financing

NeoPhore, a London-based immuno-oncology company, secured an additional £9.6 million in Series B funding, bringing the total to £31.1 million. The round was led by existing investors CPF managed by Sixth Element Capital, Claris Ventures, Astellas Venture Management, 3B Future Health Fund, and 2investAG, with the addition of three new investors: NEVA SGR, LIFTT, and Simon Fiduciaria. NeoPhore is focused on developing small molecule therapies that target the DNA mismatch repair (MMR) pathway to treat cancer. The company plans to use the funds to advance its drug discovery pipeline and deliver a candidate drug for its lead PMS2 program by early 2025.

NeoPhore Raises Additional £9.6M in Series B Extension to Advance Cancer Therapies

NeoPhore, a London, UK-based small molecule neoantigen immuno-oncology company, is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Its approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, the company aims to generate immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin andPhoreMost Ltd by the CRT Pioneer Fund.

A London-based small molecule neoantigen immuno-oncology company focused on developing novel small molecule therapies to treat cancer.

2 years ago

NeoPhore Raises Additional £9.6M in Series B Extension to Advance Cancer Therapies

ProblemHealthcare

Solution

Covered on